1. Scrip
  2. >>Business
  3. >>Strategy

What's Next For Roivant? It's Not More Publicly Traded "Vants"

 
• By Jessica Merrill

Roivant is focused on expanding its existing subsidiaries, building new ones and appointing top leadership teams to run them, but founder and CEO Vivek Ramaswamy has put a hold on more IPOs.

Machinery cogwheels, industry concept

Roivant Sciences GMBH – the umbrella company behind two of the biggest biotech IPOs in the last two years, Axovant Sciences Ltd. and Myovant Sciences Ltd. – isn't planning to launch any more public companies, at least for now.

The company's founder and CEO, Vivek Ramaswamy, a 31-year old biotech wunderkind of sorts, said he's learned some takeaways in the three years since he launched Roivant to fill a gap he saw in the sector for a big pharma-biotech hybrid

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Lundbeck Lifted By Leap In Migraine Therapy Sales

 
• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 
• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

More from Business

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

Stock Watch: Stock Watch: Lilly And Novo Duke Out Q1

 
• By Andy Smith

Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.